News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|December 8, 2020

Reducing Stress Through Mindfulness

Author(s)Neda F. Gould, PhD

Listen to the sounds of nature and release the tension you are holding.

Pay attention to places of tension and stress, then let go of it. Neda F. Gould, PhD talks through the methodical release of stress points on the body.

Dr Gould, PhD is associate director of Johns Hopkins Bayview Medical Center Anxiety Disorders Clinic, and Assistant Professor, Johns Hopkins Department of Psychiatry and Behavioral Sciences.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

placebo

Placebo Response Rates Vary Across Psychiatric Disorders

ByMasha Impallaria, MD,Ahmed Sakr, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 12th 2025

GLP1 semaglutide psychiatric disorders

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

ByJessica Walters

October 23rd 2025

LSD generalized anxiety recent study

LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD

ByMaurizio Fava, MD

October 8th 2025

Endocannabinoid System

SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes

September 24th 2025

lumateprone caplyta major depressive disorder anxious distress

Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

ByJessica Walters

September 21st 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

November in Review: Updates on the Psychiatric Treatment Pipeline

Looking Back: Key Insights from November 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD

© 2025 MJH Life Sciences^®

All rights reserved.